Page last updated: 2024-12-05

nicotinic acid hydrazide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nicotinic acid hydrazide (NAH) is a derivative of nicotinic acid, a B vitamin. It is known for its antitubercular activity and has been studied as a potential treatment for tuberculosis. NAH is synthesized by reacting nicotinic acid with hydrazine. The compound has been shown to inhibit the growth of Mycobacterium tuberculosis by interfering with the synthesis of mycolic acids, which are essential components of the bacterial cell wall. NAH has also been investigated for its potential in treating other diseases, such as cancer and Alzheimer's disease. Research on NAH continues to focus on understanding its mechanism of action, exploring its therapeutic potential, and investigating its potential side effects.'

nicotinic acid hydrazide: structural homolog of isoniazid; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11112
CHEMBL ID124495
SCHEMBL ID258390
MeSH IDM0091814

Synonyms (76)

Synonym
BB 0240607
nsc-41703
nsc41703
nsc-36088
nsc36088
(3-pyridylcarbonyl)hydrazine
nsc 18775
ccris 1374
ai3-17494
einecs 209-041-0
nicotinohydrazide
nsc 36088
3-pyridinecarboxylic acid, hydrazide
nicotinoyl hydrazide
3-pyridylcarbonylhydrazine
nicotinic acid, hydrazide
nsc18775
nicotinoyl hydrazine
nsc-18775
hydrazine, nicotinoyl-
wln: t6nj cvmz
ws 102
553-53-7
nicotinylhydrazide
3-pyridoyl hydrazine
nicotinic acid hydrazide
nicotinic hydrazide
niazid
pyridine-3-carbohydrazide
inchi=1/c6h7n3o/c7-9-6(10)5-2-1-3-8-4-5/h1-4h,7h2,(h,9,10
nicotinic hydrazide, 97%
STK034751
CHEMBL124495
N0087
AKOS000119627
NCGC00248790-01
BBL003565
M02155
NCGC00258220-01
dtxsid6020933 ,
dtxcid40933
tox21_200666
cas-553-53-7
A830602
3-pyridinecarbohydrazide
unii-af1llo72tm
af1llo72tm ,
FT-0632378
isoniazid impurity d [ep impurity]
SCHEMBL258390
pyridine-3-carboxylic acid hydrazide
nicotinylhydrazine
nicotinyl hydrazide
nicotinoylhydrazine
3-pyridinecarboxylic hydrazide
3-pyridoylhydrazine
nicotinichydrazide
W-105568
J-610086
STR00999
BS-3780
mfcd00006383
F0001-1451
F16329
nicotinic hydrazide, vetec(tm) reagent grade, 97%
nicotinic acid hydrazone
CS-W013333
SY033050
3-pyridinecarboxylic acid hydrazide
AMY836
Q27273901
A870216
n-(tert-butoxycarbonyl)phosphoramidicaciddiethylester
HY-W012617
EN300-18499
Z58981809

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency37.58990.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency44.08420.003041.611522,387.1992AID1159552; AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency27.38930.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.91460.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency13.92950.000723.06741,258.9301AID743085; AID743122
histone deacetylase 9 isoform 3Homo sapiens (human)Potency63.13380.037617.082361.1927AID1259364; AID1259388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1204120Antimalarial activity against CQ-resistant Plasmodium falciparum W2 cultivated in human type O+ red blood cells assessed as reduction in parasite infection incubated for 48 hrs by microscopy2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1059234Lipophilicity, log P of the compound2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1204114Cytotoxic activity against human HeLa cells assessed as cell viability at 10 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204118Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1059233Antitubercular activity against Mycobacterium tuberculosis BCG2013European journal of medicinal chemistry, , Volume: 70Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
AID1204117Cytotoxic activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204110Cytotoxic activity against human HepG2 cells assessed as cell viability at 1 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204115Cytotoxic activity against human HeLa cells assessed as cell viability at 1 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID733451Trypanosomicidal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 transfected with beta-D-galactosidase infected in african green monkey Vero cells assessed as growth inhibition incubated 5 days prior to beta-D-galactopyranoside addition2013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1204122Selectivity index, ratio of CC50 for human HeLa cells to IC50 for CQ-sensitive Plasmodium falciparum 3D72015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204112Cytotoxic activity against human HeLa cells assessed as cell viability at 1000 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1272277Antituberculosis activity against isoniazid-sensitive Mycobacterium tuberculosis H37Rv by microdilution method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones.
AID1149231Antibacterial activity against Mycobacterium tuberculosis assessed as growth inhibition1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID1204119Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 cultivated in human type O+ red blood cells assessed as reduction in parasite infection incubated for 48 hrs by microscopy2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204111Cytotoxic activity against human HepG2 cells assessed as cell viability at 0.1 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID733449Trypanosomicidal activity against axenic epimastigote stage of Trypanosoma cruzi Tulahuen 2 assessed as growth inhibition2013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1204108Cytotoxic activity against human HepG2 cells assessed as cell viability at 100 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1272278Antituberculosis activity against isoniazid-resistant Mycobacterium tuberculosis CN-40 by microdilution method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones.
AID1204121Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for CQ-sensitive Plasmodium falciparum 3D72015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204116Cytotoxic activity against human HeLa cells assessed as cell viability at 0.1 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID143262Minimum inhibitory concentration against Mycobacterium tuberculosis var. bovis strain at 310K, with value expressed as pMIC i.e. -log of MIC (ug/mL).2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
AID1204107Cytotoxic activity against human HepG2 cells assessed as cell viability at 1000 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204109Cytotoxic activity against human HepG2 cells assessed as cell viability at 10 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID1204113Cytotoxic activity against human HeLa cells assessed as cell viability at 100 ug/ml incubated for 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
New quinoline derivatives demonstrate a promising antimalarial activity against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (73.68)18.7374
1990's1 (1.75)18.2507
2000's3 (5.26)29.6817
2010's9 (15.79)24.3611
2020's2 (3.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.39 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]